Tecnandina’s Ecuador Facility Receives ANVISA Certification

Author(s)Pharmaceutical Technology Editors

The Grünenthal Group’s Tecnandina manufacturing plant in Ecuador has received the country’s first certification from the Regulatory Authority of Brazil.

The Grünenthal Group announced on Oct. 1, 2015 that its Tecnandina manufacturing plant in Ecuador has received certification from the Regulatory Authority of Brazil (ANVISA), making it the first production plant in Ecuador to receive ANVISA certification. The certification will allow the company to export pharmaceutical products to Brazil.

Tecnandina SA belongs to the Grünenthal Group, a research-based, pharmaceutical company headquartered in Aachen, Germany.taht offers contract manufacturing from five independent production plants throughout Europe and Latin America. The company manufactures and exports to 17 countries in Central and South America, Switzerland, and the Andean countries.

Source: Grünenthal Group

Articles in this issue

about 10 years ago

Article

Cost Inhibits CMO Adoption of Single-Use Equipment

about 10 years ago

Article

Low Temperature Needed for Complex Drug Candidates

about 10 years ago

Article

FDA Plans Pilot Projects for Drug Supply Chain Security Act

about 10 years ago

Article

Vetter Embarks on 300-Million Euro Manufacturing Expansion

about 10 years ago

Article

Sterigenics International Adds Capacity

about 10 years ago

Article

Hovione Expands Drug Substance Manufacturing

about 10 years ago

Article

Piramal Introduces Proof of Concept Service for Next Wave of ADC Growth

about 10 years ago

Article

Patheon Unveils New Brand Identity

about 10 years ago

Article

FDA Releases Guidance on Generic-Drug Development

about 10 years ago

Article

Kopcha Selected to Head FDA’s Quality Office

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!